NasdaqGS:MRNA

Stock Analysis Report

Executive Summary

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

Snowflake

Fundamentals

Flawless balance sheet with concerning outlook.

Risks

  • Moderna has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Moderna's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.1%

NasdaqGS:MRNA

0.2%

US Biotechs

0.2%

US Market


1 Year Return

n/a

NasdaqGS:MRNA

-9.1%

US Biotechs

-0.7%

US Market

No trading data on MRNA.

No trading data on MRNA.


Share holder returns

MRNAIndustryMarket
7 Day11.1%0.2%0.2%
30 Day0.7%0.9%-2.7%
90 Day-33.8%2.4%1.6%
1 Yearn/a-8.4%-9.1%1.6%-0.7%
3 Yearn/a8.3%4.6%40.0%30.9%
5 Yearn/a4.5%-0.3%53.8%36.8%

Price Volatility Vs. Market

How volatile is Moderna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moderna undervalued based on future cash flows and its price relative to the stock market?

3.49x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Moderna to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Moderna to establish if it is available at substantial discount.


Price Based on Earnings

Moderna is loss making, we can't compare its value to the US Biotechs industry average.

Moderna is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Moderna, we can't assess if its growth is good value.


Price Based on Value of Assets

Moderna is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Moderna expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

-4.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Moderna's revenue is expected to grow by 10.6% yearly, however this is not considered high growth (20% yearly).

Moderna is not considered high growth as it is expected to be loss making for the next 1-3 years.

Moderna's revenue growth is expected to exceed the United States of America market average.

Unable to compare Moderna's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Moderna's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Moderna will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Moderna performed over the past 5 years?

-78.7%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Moderna does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Moderna's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Moderna's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Moderna has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Moderna has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Moderna improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Moderna's financial position?


Financial Position Analysis

Moderna is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Moderna's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Moderna has no debt.

Moderna currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Moderna has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Moderna has sufficient cash runway for 2.2 years based on current free cash flow.

Moderna has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 47.1% each year.


Next Steps

Dividend

What is Moderna's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Moderna's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Moderna's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Moderna has not reported any payouts.

Unable to verify if Moderna's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Moderna has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Moderna's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Moderna's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Stéphane Bancel (46yo)

7.8yrs

Tenure

US$58,608,484

Compensation

Mr. Stéphane Bancel serves as Interim President of Valera LLC. Mr. Bancel is Venture Partner of Flagship Pioneering and a Trustee of the Museum of Science in Boston. Mr. Bancel provides strategic counsel a ...


CEO Compensation Analysis

Stéphane's remuneration is higher than average for companies of similar size in United States of America.

Stéphane's compensation has increased whilst company is loss making.


Management Age and Tenure

2.8yrs

Average Tenure

50yo

Average Age

The tenure for the Moderna management team is about average.


Board Age and Tenure

5.3yrs

Average Tenure

58yo

Average Age

The tenure for the Moderna board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Noubar Afeyan (56yo)

    Co-Founder

    • Tenure: 7.5yrs
    • Compensation: US$429.75k
  • Lori Henderson (57yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.3yrs
  • John Reynders

    Chief Information Officer

    • Tenure: 6.1yrs
  • Lorence Kim (45yo)

    Chief Financial Officer

    • Tenure: 5.3yrs
    • Compensation: US$9.04m
  • Stéphane Bancel (46yo)

    CEO & Director

    • Tenure: 7.8yrs
    • Compensation: US$58.61m
  • Juan Andres (54yo)

    Chief Technical Operations & Quality Officer

    • Tenure: 2.0yrs
  • Stephen Hoge (43yo)

    President

    • Tenure: 0.0yrs
    • Compensation: US$23.95m
  • Lavina Talukdar

    Head of Investor Relations

    • Tenure: 0.3yrs
  • Melissa Moore

    Chief Scientific Officer

    • Tenure: 2.8yrs
  • Jennifer Lee

    Chief Accounting Officer

    • Tenure: 0.0yrs

Board Members

  • Noubar Afeyan (56yo)

    Co-Founder

    • Tenure: 7.5yrs
    • Compensation: US$429.75k
  • Peter Hutt (84yo)

    Director

    • Tenure: 7.4yrs
    • Compensation: US$387.14k
  • Bob Langer (70yo)

    Director & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
    • Compensation: US$408.03k
  • Betsy Nabel (67yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$388.75k
  • Stéphane Bancel (46yo)

    CEO & Director

    • Tenure: 7.8yrs
    • Compensation: US$58.61m
  • Ulrich von Andrian-Werburg

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jack Szostak

    Chairman of Scientific Advisory Board

    • Tenure: 0.0yrs
  • John Aunins (58yo)

    Member of Technology Advisory Board

    • Tenure: 5.3yrs
  • Israel Ruiz (47yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$405.98k
  • Stephen Berenson (58yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$403.48k

Company Information

Moderna, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moderna, Inc.
  • Ticker: MRNA
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.672b
  • Shares outstanding: 330.18m
  • Website: https://www.modernatx.com

Number of Employees


Location

  • Moderna, Inc.
  • 200 Technology Square
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRNANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2018
0QFMUN (Boerse Muenchen)YesCommon StockDEEURDec 2018
0QFDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2018
MRNA *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNDec 2018

Biography

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 00:43
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.